Review of Myopia Management

01/02/2026

Earlier this year, Philip Cheng, B.Optom (Melb), GCOT, IACMM, FIAOMC shared his experience at the Shanghai International Optical Fair, including the myopia spectacle lenses that are being developed around the world.

Read the full story here: https://reviewofmm.com/the-proliferation-of-myopia-management-spectacles/



The University of Melbourne Myopia Clinic - Melbourne Australia

Dr. Philip Cheng shared his international experience with myopia management spectacles and what ECPs can expect in years to come.

12/31/2025

12/31/2025

Now that our countdown is over, what was YOUR favorite Review of Myopia Management story in 2025?

Share your favorites below!

12/30/2025

We made it to the end of our countdown!

Here's the most read story in 2025:

Spectacle lenses are no longer just for correction; they are a primary treatment. This article explores the massive growth of the lenslet category and why spectacles are becoming the preferred first-line therapy for many practitioners and parents alike.
https://reviewofmm.com/the-proliferation-of-myopia-management-spectacles/



The University of Melbourne Eyecare Concepts

Dr. Philip Cheng shared his international experience with myopia management spectacles and what ECPs can expect in years to come.

12/30/2025

We're coming to the end of our top-read stories of 2025!

Here's a look at story #2:

Myopia doesn't always stop at age 18. With digital strain and extended education, we’re seeing progression well into the 20s. This piece addresses how to transition pediatric patients into adult management and why we shouldn't discharge myopia control too early.
https://reviewofmm.com/how-to-manage-progressive-myopia-in-young-adults/



Brien Holden Vision Institute UNSW UNSW Optometry and Vision Science Jordan University of Science and Technology JUST

Dr. Eman Alzghoul shares the best ways for eye care professionals to treat and manage progressive myopia in young adults.

12/29/2025

We're gearing up for the final three stories in our top stories of the year countdown!

Here's #3:

Most early data on DIMS and HALT technology came from Asia. This study—one of our most read—compared how these lenses perform in European children, providing crucial evidence that these designs are globally effective across different ethnicities.
https://reviewofmm.com/comparison-of-performance-of-myopia-control-spectacles-in-european-children/

This research review compares the myopia control performance of two spectacle lens designs in European children and adolescents.

12/29/2025

Story #4 in our top stories of 2025 countdown:

Repeated low-level red light therapy is the talk of the town. This article breaks down the 2025 research on efficacy and the ongoing debate regarding the optimal treatment intervals for safety.
https://reviewofmm.com/the-latest-in-red-light-therapy/


Brien Holden Vision Institute Australian College of Optometry

Dzung Tran shared the latest research in red light therapy, including safety, combined treatments, and pre-myopes.

12/28/2025

We're halfway through our most-read articles of 2025!

Check out story #5:

Why does outdoor time work? It’s all about the dopamine. This deep dive into retinal biology explains how light exposure triggers the neurotransmitters that physically tell the eye to stop growing.
https://reviewofmm.com/retinal-neurotransmitter-systems-in-myopia-understanding-the-role-of-dopamine-and-related-pathways/



Brien Holden Vision Institute UNSW UNSW Optometry and Vision Science

Nicole Liu breaks down the role of dopamine and retinal neurotransmitters in progressive myopia in young children.

12/28/2025

We're counting down the top stories of 2025, and we've made it to #6 on the list:

Dr. Michael Lipson and Dr. Bruce Koffler created a roadmap for myopia management treatment recommendations. Read the full story to see how they recommend treating patients with pre-myopia and high myopia:
https://reviewofmm.com/the-lipson-koffler-myopia-management-treatment-protocol/

This articles features the Lipson Koffler Myopia Management Treatment Protocol, highlighting how ECPs should treat myopia patients.

12/27/2025

#7 on the most-read stories of 2025:

The 20-20-20 rule may be the most common advice given to patients, but what does the science say? This article from Medical Co-Editor Kevin Chan, OD, MS, FAAO, IACMM re-evaluates the 20-20-20 rule in the context of modern "near-work" and whether it’s enough to actually slow axial elongation.
https://reviewofmm.com/20-20-20-rule/

In this month's column, Dr. Kevin Chan breaks down the myths and best practices surrounding the 20-20-20 rule.

12/27/2025

Continuing the countdown of our most-read articles of 2025, here's article #8:

China’s reclassification of red light therapy devices from Class II to Class III was big news for the industry. This story covers the global implications for safety standards and what ECPs need to know about device regulation.
https://reviewofmm.com/a-wake-up-call-regulatory-changes-for-red-light-therapy-china/

This link will take you to a page that’s not on LinkedIn

12/26/2025

#9 in the countdown:

Medical Co-Editor Ashley Tucker, OD, FAAO, FSLS, ABO Diplomate broke down what the FDA approval of EssilorLuxottica's Stellest spectacle lenses means for ODs moving forward.
https://reviewofmm.com/now-what-turning-essilors-stellest-approval-into-action/

This month, Medical Editor Dr. Ashley Tucker explores what the approval of Essilor's Stellest lenses means for the eye care industry.